Patent · US Active

HCMV entry inhibitors

US11390661B2 · kind B2 · utility

0Cited by

7References

9Claims

0Family size

Assignee

AICURIS ANTI-INFECTIVE CURES AG · DE

Inventors

Christian Sinzger · Reutlingen, DE
Cora STEGMANN · Ulm, DE
Kerstin LAIB SAMPAIO · Dettingen, DE
Barbara ADLER · Munich, DE

Key dates

Filing date	Jun 27, 2017
Grant date	Jul 19, 2022
Priority date	—
Expiry date	Aug 23, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Subject matter of the present invention is a soluble PDGFR-alpha-Fc chimera or a PDGFR-alpha derived peptide or an anti-PDGFR-alpha antibody or a PDGFR-alpha antibody fragment or anti-PDGFR-alpha non-Ig scaffold for inhibiting HCMV entry for use in a method of treatment in a subject that has been infected by HCMV or for use in a method of prophylaxis of HCMV infection in a subject that has not yet been infected by HCMV.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.